financetom
Business
financetom
/
Business
/
Arvind Fashions reports Q3 net loss of Rs 65.62 cr
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Arvind Fashions reports Q3 net loss of Rs 65.62 cr
Feb 3, 2021 7:10 AM

Arvind Fashions Ltd (AFL) on Wednesday reported a consolidated net loss of Rs 65.62 crore in the third quarter ended December 31, 2020. The company had posted a net loss of Rs 48.26 crore in the year-ago period, AFL said in a BSE filing.

Its net sales during the period under review was at Rs 911.13 crore. It was Rs 1,062.28 crore in the year-ago period. Commenting on the results AFL MD and CEO J Suresh said with better than expected sales recovery through improved footfalls during the festival period which has resulted in significantly improved profitability and a cash breakeven for continuing business in Q3 FY21.

”Our focus on digital and omni-channel initiatives and a deep cost focus continue to deliver robust outcomes. At the back of strong Q3, we expect H2 FY21 to be significantly better in terms of sales & profitability growth, he added. Arvind Fashions said its board has also approved issue of equity shares for an amount up to Rs 200 crore on rights basis.

”The board evaluated various options and was of the view that rights issue would be an equitable mode of fundraising as it gives its shareholders an equal opportunity to participate in the growth of the company. ”The company intends to utilise the funds to meet its objectives of strengthening its balance sheet and for general corporate purposes, including working capital for growth,” the company added.

Shares of Arvind Fashions Ltd were trading 2.05 percent lower at Rs 146 apiece on BSE.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Axon to Acquire Carbyne, Uniting Cloud Infrastructure and AI to Redefine the 911 Experience
Axon to Acquire Carbyne, Uniting Cloud Infrastructure and AI to Redefine the 911 Experience
Nov 4, 2025
Acquisition brings next-generation, cloud-native 911 technology into the Axon ecosystem, uniting connected devices, real-time communications, and digital evidence from call to courtroom. SCOTTSDALE, Ariz., Nov. 4, 2025 /PRNewswire/ -- Axon , the global public safety technology leader, today announced it has entered into a definitive agreement to acquire Carbyne, an innovative emergency communications and response platform serving hundreds of agencies...
Amgen profit beats estimates, weight-loss data due by year-end
Amgen profit beats estimates, weight-loss data due by year-end
Nov 4, 2025
Nov 4 (Reuters) - Amgen ( AMGN ) on Tuesday reported quarterly financial results that beat Wall Street expectations as product sales rose 12%, offsetting higher operating expenses related to experimental weight-loss drug MariTide and a higher tax rate. The California-based biotech company's third-quarter revenue also rose 12% from a year earlier to $9.56 billion. Adjusted earnings per share increased...
Rivian tops revenue expectations as buyers rush before EV incentive expiry
Rivian tops revenue expectations as buyers rush before EV incentive expiry
Nov 4, 2025
* Rivian's Q3 revenue boosted by pre-expiry EV tax incentive rush * Adjusted net loss smaller than analyst expectations * Company lays off 4.5% of workforce due to rising costs By Akash Sriram and Abhirup Roy Nov 4 (Reuters) - Rivian Automotive ( RIVN ) surpassed Wall Street expectations for third-quarter revenue on Tuesday, fueled by strong deliveries as U.S....
Amgen profit beats estimates, weight-loss data due by year-end
Amgen profit beats estimates, weight-loss data due by year-end
Nov 4, 2025
(Reuters) -Amgen ( AMGN ) on Tuesday reported quarterly financial results that beat Wall Street expectations as product sales rose 12%, offsetting higher operating expenses related to experimental weight-loss drug MariTide and a higher tax rate. The California-based biotech company's third-quarter revenue also rose 12% from a year earlier to $9.56 billion. Adjusted earnings per share increased 1% to $5.64....
Copyright 2023-2026 - www.financetom.com All Rights Reserved